A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD

NCT05004688 PHASE2 COMPLETED Results posted

A study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older with mild cognitive impairment and mild-to-moderate to Alzheimer's disease.

Details

Lead sponsor	Steven E Arnold, MD
Phase	PHASE2
Status	COMPLETED
Enrolment	15
Start date	Fri Mar 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jan 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Mild Cognitive Impairment
• Mild Dementia
• Moderate Dementia
• Alzheimer Disease

Interventions

• Biological/Vaccine: Bacillus Calmette-Guerin (BCG)

Countries

United States